Clinical response to TIL therapy in PD-1-naïve patients vs PD-1 progressors
| No prior αPD-1 | Prior αPD-1±αCTLA-4 | |
| n=32 | n=23 | |
| Response rate* | 42% | 32% |
| Median OS (months) | 19.6 | 14 |
| Median PFS (months) | 3.9 | 2.8 |
| DOR both CR and PR, median (months) | 32.2 | 7.6 |
| # CR | 5 | 1 |
| DOR median (months) | 54.8 | 41‡ |
| DOR min (months) | 13.2 | 41‡ |
| DOR max (months) | 83.1 | 41‡ |
| DOR range (months) | (13.2–83.1‡) | (41‡) |
| # PR | 8 | 6 |
| DOR median (months) | 11.3 | 6.2 |
| DOR min (months) | 7.8 | 2.7 |
| DOR max (months) | 76.1‡ | 28.6 |
| DOR range (months) | (7.8–76.1‡) | (2.7–28.6) |
| # Ongoing responses (CR/PR) | 5 (3/2) | 2 (1/1) |
*One patient in each group was not evaluable for response.
†Duration of response.
‡Ongoing response.
CR, complete response; DOR, duration of response; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival; PR, partial response; TIL, tumor-infiltrating lymphocytes.